- Home
- RLX vs XENE Comparison
RLX vs XENE Comparison
Compare RLX & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLX
- XENE
- Stock Information
- Founded
- RLX 2018
- XENE 1996
- Country
- RLX China
- XENE Canada
- Employees
- RLX N/A
- XENE N/A
- Industry
- RLX Medicinal Chemicals and Botanical Products
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- RLX Health Care
- XENE Health Care
- Exchange
- RLX Nasdaq
- XENE Nasdaq
- Market Cap
- RLX 2.6B
- XENE 3.0B
- IPO Year
- RLX 2021
- XENE 2014
- Fundamental
- Price
- RLX $1.70
- XENE $39.83
- Analyst Decision
- RLX Strong Buy
- XENE Strong Buy
- Analyst Count
- RLX 1
- XENE 10
- Target Price
- RLX $2.76
- XENE $57.30
- AVG Volume (30 Days)
- RLX 4.5M
- XENE 382.6K
- Earning Date
- RLX 11-15-2024
- XENE 11-12-2024
- Dividend Yield
- RLX 0.59%
- XENE N/A
- EPS Growth
- RLX 639.71
- XENE N/A
- EPS
- RLX 0.07
- XENE N/A
- Revenue
- RLX $307,798,132.00
- XENE N/A
- Revenue This Year
- RLX $115.02
- XENE N/A
- Revenue Next Year
- RLX $45.35
- XENE $1,600.08
- P/E Ratio
- RLX $23.96
- XENE N/A
- Revenue Growth
- RLX 113.81
- XENE N/A
- 52 Week Low
- RLX $1.50
- XENE $28.20
- 52 Week High
- RLX $2.40
- XENE $50.99
- Technical
- Relative Strength Index (RSI)
- RLX 55.45
- XENE 39.07
- Support Level
- RLX $1.58
- XENE $41.42
- Resistance Level
- RLX $1.68
- XENE $44.61
- Average True Range (ATR)
- RLX 0.05
- XENE 1.53
- MACD
- RLX 0.01
- XENE -0.36
- Stochastic Oscillator
- RLX 69.44
- XENE 2.99
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.